Please make sure that you select the correct MabThera® (rituximab) formulation

SUBCUTANEOUS INJECTION

For use in non-Hodgkin's lymphoma ONLY†*

MabThera 1400 mg solution for subcutaneous injection



Withdraw directly from the vial and administer by subcutaneous injection

Check for the specific MabThera SC packaging characteristics before use:

1. Red labelling: **'For subcutaneous use only', 'solution for subcutaneous injection'** and **'SC'**
2. Pink flip-off cap

INTRAVENOUS INFUSION

For use in all MabThera-approved indications†

MabThera 100 mg concentrate for solution for infusion
MabThera 500 mg concentrate for solution for infusion

Dilute with 0.9% NaCl or 5% glucose and administer by intravenous infusion

* MabThera SC is not indicated as monotherapy in patients with stage III–IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.
† Please refer to the Summary of Product Characteristics (available at www.medicines.ie) for further information.

This material is provided by Roche Products (Ireland) Limited as a licence requirement for this medicine and forms part of the MabThera Risk Management Plan.

Reporting of suspected adverse events: Reporting suspected adverse events after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse events (see details below). **In the event of a suspected adverse event, please report it to:** The Drug Surveillance Centre, Roche Products (Ireland) Limited, 3004 Lake Drive, Citywest, Naas Road, Dublin 24. Telephone: (01) 4690700, Fax: (01) 4690793, Email: ireland.drug_surveillance_centre@roche.com. **Alternatively, suspected adverse reactions should be reported to:** The Pharmacovigilance Section, The Irish Medicines Board, Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2. Telephone: (01) 6764971, Fax: (01) 6762517, Email: imbpharmacovigilance@imb.ie, website: www.imb.ie.
As MabThera is a biologic medicine, healthcare professionals are encouraged to report adverse events by brand name, batch number and expiry date.

Roche

Published by
Roche Products (Ireland) Limited.

IE Version 1.0 April 2014
p02/04/14